Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
1 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
17 Apr 24
S-3
Shelf registration
8 Apr 24
8-K
Regulation FD Disclosure
8 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
7 Mar 24
S-8
Registration of securities for employees
8 Feb 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Regulation FD Disclosure
11 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
9 Nov 23
8-K
Departure of Directors or Certain Officers
10 Oct 23
D
$25.00 mm in equity, sold $25.00 mm, 1 investor
11 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023
8 Aug 23
8-K
Astellas and Poseida Therapeutics Announce Strategic
7 Aug 23
UPLOAD
Letter from SEC
17 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
22 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
8-K
Termination of a Material Definitive Agreement
1 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
9 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Departure of Directors or Certain Officers
13 Apr 23
8-K
Changes in Registrant's Certifying Accountant
30 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
9 Mar 23
8-K
Regulation FD Disclosure
22 Feb 23
8-K
Poseida Therapeutics Announces Board Change
31 Jan 23
S-8
Registration of securities for employees
12 Jan 23
8-K
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
6 Dec 22
8-K
Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors
1 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
10 Nov 22
Latest ownership filings
4
Syed Ali-aamir Rizvi
3 Apr 24
3
Syed Ali-aamir Rizvi
3 Apr 24
4
Johanna Mylet
4 Mar 24
4
Mark J Gergen
4 Mar 24
4
HARRY J LEONHARDT
4 Mar 24
4
Brent Warner
4 Mar 24
SC 13G/A
FMR LLC
9 Feb 24
4
Mark J Gergen
2 Feb 24
SC 13G
BlackRock Inc.
31 Jan 24
4
Kristin Yarema
4 Jan 24
4
Mark J Gergen
4 Jan 24
SC 13D
Astellas US LLC
14 Aug 23
4
Cynthia Collins
16 Jun 23
4
John P. Schmid
16 Jun 23
4
Marcea Bland Lloyd
16 Jun 23
4
CHARLES M BAUM
16 Jun 23
4
Luke Corning
16 Jun 23
4
Rafael Amado
2 May 23
3
Rafael Amado
14 Apr 23
4
Kristin Yarema
12 Apr 23
3
Kristin Yarema
12 Apr 23
4
Brent Warner
2 Mar 23
4
Johanna Mylet
2 Mar 23
4
HARRY J LEONHARDT
2 Mar 23
4
Mark J Gergen
2 Mar 23
SC 13G/A
FMR LLC
9 Feb 23
4
Eric Ostertag
3 Feb 23
4
Mark J Gergen
3 Feb 23
5
Eric Ostertag
17 Jan 23
4
Change in insider ownership
10 Aug 22
4
Eric Ostertag
10 Aug 22
4
Eric Ostertag
5 Aug 22
4
Cynthia Collins
17 Jun 22
4
CHARLES M BAUM
16 Jun 22
4
Luke Corning
16 Jun 22
4
John P. Schmid
16 Jun 22
4
Marcea Bland Lloyd
16 Jun 22
3
CHARLES M BAUM
18 May 22
SC 13D/A
Pentwater Capital Management LP
25 Apr 22
4
Kerry D. Ingalls
18 Mar 22